Alphatec Holdings, Inc. (Nasdaq: ATEC) reported a 25% growth in total revenue for the full year 2025, reaching approximately $764 million.
The company expects to achieve a total revenue of $890 million in the full year 2026, representing a 17% growth compared to 2025.
The acquisition of exclusive U.S. distribution rights for Theradaptive's OsteoAdapt®, a next-generation rhBMP-2 solution, enhances Alphatec's procedural offerings.
Total Revenue Growth
Preliminary total revenue for 2025 increased by approximately 25%.
2026 Revenue Outlook
Anticipated total revenue for 2026 is $890 million, projecting a 17% growth.
Exclusive Distribution Rights
Alphatec obtained exclusive U.S. distribution rights for Theradaptive's OsteoAdapt®, expanding procedural options.
- Strong surgeon adoption contributed to a 26% growth in surgical revenue for 2025.
- Alphatec's focus on driving revenue growth has led to continued leverage within the company.
- The addition of OsteoAdapt is expected to address market concentration challenges of rhBMP-2.
- The company maintains its adjusted EBITDA guidance at $91 million for the full year 2025, reflecting financial strength.
Alphatec Holdings, Inc. showcases impressive growth in total revenue, positioning the company for a promising 2026. The acquisition of exclusive distribution rights enhances its product range and growth potential within the spine care market.